Results 71 to 80 of about 1,343,260 (212)
Kinetic properties of “dual” orexin receptor antagonists at OX1R and OX2R orexin receptors [PDF]
Orexin receptor antagonists represent attractive targets for the development of drugs for the treatment of insomnia. Both efficacy and safety are crucial in clinical settings and thorough investigations of pharmacokinetics and pharmacodynamics can predict contributing factors such as duration of action and undesirable effects.
Callander, GE +15 more
openaire +3 more sources
Hip Fracture Risk of Lemborexant and Suvorexant in Comparison With Z‐Drugs: A Target Trial Emulation
ABSTRACT Background Lemborexant and suvorexant are widely used dual orexin receptor antagonists (DORAs) for the pharmacological treatment of insomnia. Although they are generally considered safer than benzodiazepine receptor agonists (Z‐drugs) regarding adverse events including hip fractures, evidence from direct comparisons remains limited. This study
Yuichiro Matsuo +5 more
wiley +1 more source
Purpose: The interaction of orexinergic neurons with the opioidergic system and their effects on morphine analgesia and tolerance have not been fully elucidated.
Baser, Tayfun +5 more
core +1 more source
Summary The world‐wide prevalence of insomnia disorder reaches up to 10% of the adult population. Women are more often afflicted than men, and insomnia disorder is a risk factor for somatic and mental illness, especially depression and anxiety disorders.
Dieter Riemann +13 more
wiley +1 more source
Effect of Orexin-A on Post-ischemic Glucose Intolerance and Neuronal Damage
Orexin-A is a newly identified neuropeptide expressed in the lateral areas of the hypothalamus that plays a role in various physiological functions, including regulation of glucose metabolism.
Shinichi Harada +2 more
doaj +1 more source
Narcolepsy and rapid eye movement sleep
Summary Since the first description of narcolepsy at the end of the 19th Century, great progress has been made. The disease is nowadays distinguished as narcolepsy type 1 and type 2. In the 1960s, the discovery of rapid eye movement sleep at sleep onset led to improved understanding of core sleep‐related disease symptoms of the disease (excessive ...
Francesco Biscarini +4 more
wiley +1 more source
Role of orexin receptors in histamine- and chloroquine-induced pruriceptive processing
It is known that orexin peptides are involved in nociceptive processing, while little is known about the roles of these peptides in itch processing. To reveal the functions of orexin peptides in pruriceptive processing, orexin A (OX-A) and orexin B (OX-B)
Anna Kanemaru-Kawazoe +7 more
doaj +1 more source
Background Polycystic ovary syndrome (PCOS) is a prevalent endocrine disorder without definitive treatments. Orexin and Substance-P (SP) neuropeptides can affect the ovarian steroidogenesis.
Somayeh Kouhetsani +2 more
doaj +1 more source
Ageing‐related modification of sleep and breathing in orexin‐knockout narcoleptic mice
Summary Narcolepsy type‐1 (NT1) is a lifelong sleep disease, characterised by impairment of the orexinergic system, with a typical onset during adolescence and young adulthood. Since the wake–sleep cycle physiologically changes with ageing, this study aims to compare sleep patterns between orexin‐knockout (KO) and wild type (WT) control mice at ...
Stefano Bastianini +7 more
wiley +1 more source
The Dual Orexin Receptor Antagonist Almorexant Induces Sleep and Decreases Orexin-Induced Locomotion by Blocking Orexin 2 Receptors [PDF]
Orexin peptides activate orexin 1 and orexin 2 receptors (OX(1)R and OX(2)R), regulate locomotion and sleep-wake. The dual OX(1)R/OX(2)R antagonist almorexant reduces activity and promotes sleep in multiple species, including man. The relative contributions of the two receptors in locomotion and sleep/wake regulation were investigated in mice.Mice ...
Géraldine M, Mang +8 more
openaire +2 more sources

